These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38085056)

  • 21. Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.
    Semmes EC; Shen E; Cohen JL; Zhang C; Wei Q; Hurst JH; Walsh KM
    Cancer Med; 2020 Nov; 9(21):8216-8225. PubMed ID: 32945147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
    Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
    Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in
    Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J
    Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines.
    Mercatelli D; Balboni N; Palma A; Aleo E; Sanna PP; Perini G; Giorgi FM
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33525507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
    Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
    J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
    Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
    Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
    Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
    Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
    [No Abstract]   [Full Text] [Related]  

  • 36. Impaired Antitumor Immune Response in
    Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
    Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
    Bhardwaj N; Das G; Srinivasan R
    J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
    Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
    J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting amplification of
    Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
    Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
    Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
    PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.